





EVALUATION OF THERAPY FOR CANINE INTRACRANIAL NEOPLASIA USING  



















Submitted in partial fulfillment of the requirements 
for the degree of Master of Science in VMS - Pathobiology 
in the Graduate College of the  










 Associate Professor Timothy M. Fan, Chair 
Professor Paul J. Hergenrother  
Professor Anne M. Barger 







Canine central nervous system tumors can develop deeply within the brain parenchyma, 
precluding surgical resection and limiting therapeutic options. PAC-1 is a novel, blood-brain 
barrier penetrant, pro-apoptotic small molecule activator of procaspase-3 (PC-3), with orphan 
drug status for the treatment of human glioblastoma multiforme. PC-3 is frequently 
overexpressed in malignantly transformed tissues, providing an opportunity to selectively induce 
apoptosis in cancer cells with dysregulated upstream apoptotic circuitry. This study evaluates the 
in vitro activity of PAC-1 against a panel of brain tumor cells, and the feasibility of combining 
PAC-1 with radiation therapy in an in vivo murine glioma model.   
Immunohistochemical characterization of PC-3 was performed in 21 normal canine 
brains and approximately 700 canine and human intracranial neoplasms. Murine, canine, and 
human glioma cell lines were evaluated for PC-3 expression and in vitro sensitivity to PAC-1 
and radiation.  
PC-3 is overexpressed in canine intracranial neoplasms and high-grade human 
astrocytomas relative to normal brain tissues. Immortalized glioma cell lines show in vitro 
sensitivity to PAC-1 and radiation monotherapies at biologically relevant exposures. Murine 
gliomas appear to be sensitive to PAC-1 and radiation monotherapies, as well as to combination 
therapy with both PAC-1 and radiation therapy; however, murine study results are not 
statistically significant at this time.  
Investigation of therapeutic approaches that combine PAC-1 with radiation therapy 
and/or temozolomide will further elucidate its therapeutic potential in murine models and canine 
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Primary brain tumors are a significant cause of morbidity and mortality in small animal 
companion animals, affecting up to 4.5% of dogs.1 The most common CNS brain tumors in dogs 
are meningiomas (~45-50%), gliomas (~40-70%), and choroid plexus neoplasms (~5-7%).1–3  
Treatment options for dogs with brain cancer include radiation therapy, chemotherapy, or a 
combination.4–8 Treatment outcomes for brain tumors that allow maximal resection are 
associated with increased survival in both animals and humans.  In contrast, intra-axial tumors, 
primarily gliomas and some choroid plexus carcinomas, develop intra-axially and deep within 
the brain parenchyma, complicating surgical resection.9–11 If owners are financially constrained 
and cannot pursue radiation therapy, or if the patient is at increased anesthetic risk, palliative 
treatments with corticosteroids and anticonvulsants remain the only short-term management 
options available to pet owners.  Median survival time in dogs with intra-axial tumors is 
approximately 70 days with palliative therapies, depending on tumor type and location.12 Human 
patients with a diagnosis of grade IV astrocytoma (glioblastoma multiforme) can expect a 
median survival time of approximately 1-2 years, despite aggressive therapy with surgical 
cytoreduction, stereotactic radiation, and chemotherapy.13–16   
In both people and companion animals, there is a need to identify cost-effective and 
therapeutically efficacious treatment modalities for brain tumors, especially those that are 
difficult to resect, with the aims of significant improvement in both quality of life and survival 
time.  Ideally, in the age of personalized medicine, we utilize therapeutics that directly target 
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molecular aberrations within the cancer cell population.  In both the human and canine 
intracranial neoplasia literature, evasion of apoptosis is a common cellular transformation.17–21  
PAC-1 is a blood-brain barrier penetrant, small molecule, pro-apoptotic activator of 
procaspase-3 (PC-3), that is simple to synthesize and inexpensive.22  Importantly, cellular 
sensitivity to induction of apoptosis with PAC-1 is associated with the resting cellular PC-3 
concentration, and as many malignantly transformed cells have elevated PC-3 levels, PAC-1 
therapy allows selective induction of apoptosis in these malignantly transformed cells.23   
In this study, we will document the PC-3 immunohistochemical staining properties of the 
normal canine brain, and compare these properties with malignantly transformed tissues. 
Additionally, since similar tumor histologies affect both dogs and humans, results from this 
study may be useful to both veterinary and human oncologists; therefore, we will also compare 
PC-3 immunostaining normal human brain tissue to common intracranial neoplasms. We will 
characterize the response of immortalized human, murine, and canine glioma cell lines to PAC-1 
and radiation therapy. Finally, we will begin to explore the efficacy of PAC-1 and radiation 








2.1 The incidence of intracranial neoplasia in dogs 
While the true incidence of brain tumors in dogs is unknown, autopsy estimates place the 
incidence around 1-4.5%, generally occurring in middle-aged to aged dogs.1, 12, 24 This estimate 
is similar to the approximately 2% incidence previously reported in humans.3, 25 While there is 
variation in the precise percentages of different tumor types in the literature, approximately 50% 
of primary canine intracranial neoplasms are meningiomas and 40-70% are gliomas.3, 12  
Meningiomas are overrepresented in Golden Retrievers, Boxers, and Miniature Schnauzers, 
while astrocytomas are overrepresented in Boxers, Boston Terriers, and Bulldogs.3 
 
2.2 Brain tumor histologies 
Brain tumors may arise from many diverse cells within the central nervous system. As 
previously noted, the most common canine brain malignancies are gliomas and meningiomas; 
similarly, these are the most common brain tumor histologies in humans.26  
Gliomas arise from neuroglial cells, which have a wide range of functions including 
modulation of nerve signal propagation, providing a scaffold for neural development, and aiding 
in recovery from injury. Astrocytes are named for their elaborate processes that give them a star-
like appearance; these cells provide an appropriate chemical environment for neural signaling, 
and when they are malignantly transformed, give rise to astrocytomas.27 Astrocytomas affect 
middle-aged dogs, with a median age of onset of 8.6 years, although they have been documented 
in very young dogs.26 Oligodendrocytes myelinate axons, which increases the speed of action 
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potentials within the nervous system; these cells give rise to oligodendrogliomas.27 Images of 
these cells may be seen in Figure 2.1. Because glial cells are located within the brain 
parenchyma, tumors that arise from these cells also grow within the parenchyma, complicating 
surgical resection.28 
Meningiomas arise from arachnoid cap cells in the arachnoid mater, one of the layers of 
the meninges.26 The meninges are three protective layers that surround the brain, brain stem, and 
spinal cord.29 These lesions tend to be compressive rather than infiltrative, although up to 27% of 
these lesions may invade the brain tissue, consistent with malignant lesions.26, 30 An image of the 
meninges may be seen in Figure 2.2. Most meningiomas occur in older dogs, aged 10-11 years, 
although they may be seen in younger dogs as well. Canine meningiomas are strikingly similar to 
their human counterparts, having similar imaging, gross and histological appearances, as well as 
similar expression of growth factors, receptors, and cytogenetic expressions.26   
 
2.3 Challenges in developing therapeutics for brain cancer 
The diagnosis of malignant brain cancer is dreaded by patients, physicians, and 
veterinarians alike. In brain cancer, both natural disease progression and therapeutic side effects 
may cause significant neurological side effects, which markedly alter the patient’s quality of life 
and interfere with everyday tasks.14, 24  
The development of novel therapeutics is particularly challenging for the central nervous 
system due to the blood brain barrier, which prevents many therapeutics, including many of our 
traditional chemotherapeutic agents, from moving into the brain parenchyma via systemic 
circulation. Relative to peripheral capillaries, endothelial cells in the brain have continuous tight 
junctions without fenestrations, and are surrounded by pericytes and astrocytic end feet which 
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mediate vessel permeability. These vessels also have high electrical resistance, which prevent 
polar and ionic substances from crossing the barrier (Figure 2.3).31, 32  
Despite recent advances in understanding cancer on a genomic level, the pathway to 
novel therapeutic discovery and production is fraught with failure. Because of the complex host 
and tumor interplay involved in the pathogenesis of cancer, in vivo modeling is necessary to fully 
evaluate novel therapeutic methods. Only about 1/3 of research completed in animal models is 
later tested in human trials, and of these, as few as 8% of drugs pass Phase I clinical trials 
successfully.33 Unfortunately, even following significant time and economic investment, 
therapeutic agents that seem promising in animal models and Phase I trials may ultimately fail to 
show efficacy in phase II/III clinical trials.34, 35 In essence, these trials fail because the animal 
models that are widely in use fail to fully recapitulate the biology of human tumors.  
The FDA has only approved 2 new drugs for the treatment of high-grade gliomas in humans over 
the past 30 years—temozolomide and bevacizumab. The latter is of questionable efficacy.3  
Currently, the most widely available and utilized model for tumorigenesis is the 
experimental rodent model. There are two primary rodent tumor models: genetically engineered 
mice in which oncogenes or tumor suppressor genes lead to spontaneous oncogenesis, and 
engrafted tumor models, in which primary tumor cells or cell lines are implanted into the animal. 
Although spontaneous models mirror the pathogenesis of primary human glioma more closely 
than engrafted models, they are poorly reproducible, require long latency periods prior to the 
development of a tumor, and require advanced in vivo imaging techniques.36 The use of 
genetically engineered mice is also a double-edged sword; while we may be able to engineer a 
mouse with a specific dysfunctional gene without interference of other genetic factors, this may 
not adequately reflect the heterogeneity found in spontaneous tumors.34 By contrast, engrafted 
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models may lack characteristic histological traits that are seen in spontaneous human gliomas, 
and they often require implantation in an immunocompromised mouse model, which fails to 
account for a normal host immune reponse.26, 34, 36 Additionally, as cells intended for grafts are 
cultured over time, genetic drift may occur, and the engrafted tumor may become more or less 
malignant, or may acquire molecular changes that make the cells more or less susceptible to the 
therapeutic of interest; these factors may lead to substantial variation in experimental 
outcomes.34 
 In the engrafted tumor model, graft cells may come from cell lines grown in culture, 
spheroids from minced biopsy specimens, or from “heterotopic to orthotopic” models, in which 
tumors are first established by transplanting human biopsies into the flanks of immunodeficient 
mice.34, 37 Although the heterotopic to orthotopic model may be simpler and more reliable than 
the spheroid model, lesions formed from these tumors often lack necrotic features associated 
with brain tumors, and fail to show proliferating endothelial cells, which are a common target in 
modern cancer therapy.26, 34 Neurospheres are cancer stem-like cells that connote significant 
advantages over monolayer cell cultures, and are akin to the stem-like cells that are commonly 
highly resistant to conventional therapies such as chemotherapy and radiation therapy; such cells 
have been identified in the case of a Boxer Dog’s glioblastoma multiforme (GBM) tumor.26,38 
Importantly, spheres more commonly maintain the original molecular makeup of the tumor and 
are more genetically stable. Additionally, they readily create extensive infiltrative lesions when 





2.4 Comparative oncology and dogs as a model for human brain cancer 
 Comparative oncology is a growing field that focuses on the study of spontaneous, or 
naturally occurring, cancers in non-human species, as a complementary model for human cancer 
research efforts. As outlined previously, spontaneous canine brain tumors occur with similar 
frequency to human brain tumors, and they develop a wide variety of tumor histologies that are 
strikingly similar to those observed in humans.24, 26, 35 Additionally, dogs are the most widely 
studied companion animal species right now, primarily due to the degree of genomic similarity 
and shared environment with humans.35 Dogs have significant anatomic and physiological 
similarities to humans, and in modern veterinary medicine, pet owners are often very motivated 
to seek new treatment options for their pets, particularly if clinical trials may provide a survival 
benefit and may help defray the cost of experimental therapy. Finally, dogs are significantly 
larger than mice or rats, making surgical studies more readily applicable and relevant to human 
oncology.26  Thus, dogs are poised as an excellent model species to advance cancer therapy in 
both human and animal medicine.  
 
2.5 Challenges in standard of care therapy for brain tumors in dogs 
Treatment outcomes for brain tumors that allow maximal resection are associated with 
increased survival in both animals and humans.  In contrast, intra-axial tumors, primarily gliomas 
and some choroid plexus carcinomas, develop intra-axially and deep within the brain 
parenchyma, complicating surgical resection.10, 11, 39  
For example, glioblastoma multiforme (GBM) is the most aggressive brain cancer in both 
dogs and humans, and it is a deadly disease with a uniformly dismal prognosis.38 Despite its 
invasive nature, which often precludes complete surgical resection, surgery is often indicated in 
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human GBM patients to relieve the mass effect leading to neurological symptoms, achieve 
cytoreduction, and provide adequate tissue to allow complete characterization of the neoplastic 
cell population.14 Surgery is generally followed by chemotherapy and radiation therapy. 
Radiation therapy has been shown to prolong survival in multiple studies, whereas the efficacy 
of surgical resection is a matter of debate.16 When used in combination with radiation therapy, 
nitrosourea-based chemotherapy improved median survival time by 2 months, whereas 
temozolomide improved median survival time by 2.5 months. Despite these therapeutic 
advances, the median survival time in humans remains persistently low at 14.6 months for GBM 
patients.14, 16 Temozolomide has been evaluated with pet dogs diagnosed with lymphoma, but it 
is very costly, and this is a practical limiting factor in veterinary medicine.40  
In pet dogs, the standard of care for intracranial neoplasia is undetermined, particularly 
for patients with invasive brain tumors that are difficult to surgically excise. This is due to a 
variety of factors, including delayed therapy, which may limit available therapeutic options; 
paucity of data in the literature, which limits our ability to make meaningful conclusions about 
available therapies; and the necessity of anesthesia for many procedures, which increases 
treatment cost for pet owners and introduces anesthesia-related risk for veterinary patients.  
One of the most common presenting clinical presentations of a brain tumor in a human is 
a new-onset, lateralized, and severe headache that is progressive;14 this clinical symptom, while 
present, may be difficult for a pet owner or even a seasoned veterinary practitioner to recognize, 
and many brain tumors may go unrecognized for prolonged time periods in pet dogs. 
Unfortunately, this delay in treatment may significantly undermine the array of available 
therapeutic options, and these animals may present at a later date with severe clinical signs, such 
as seizures, mentation changes, vestibular signs, or vision loss.24  
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Advances in veterinary neuro-oncology are largely due to improvements in detection 
with imaging techniques, surgical optimization, and chemotherapy to a lesser extent.3 Most 
studies that evaluate therapeutic strategies in canine brain cancer are descriptive and 
retrospective, with few patients for evaluation and a lack of standardization in imaging and 
tumor biopsy endpoints. Additionally, the time of death in veterinary medicine is determined by 
the owner’s decision to euthanize, which leads to additional variability in our studies as 
compared to the human literature.26  
Some procedures used routinely in the diagnosis and treatment of canine intracranial 
neoplasia (MRI, radiation therapy) require general anesthesia to immobilize the patient, and 
these procedures are both costly and potentially dangerous for animals that are at increased 
anesthetic risk. Unfortunately, veterinary care is also limited by the pet owner’s disposable 
income and time available to treat a pet, especially when treatment requires specialized staff or 
equipment, such as radiation therapy or infused chemotherapeutic drugs. If owners are 
financially constrained and cannot pursue radiation therapy, or if the patient is at increased 
anesthetic risk, palliative treatments with corticosteroids and anticonvulsants remain the only 
short-term management options available to pet owners.  Median survival time in dogs with 
intra-axial tumors is approximately 70 days with palliative therapies, depending on tumor type 
and location.12 There is a distinct need to identify therapeutic approaches that are both cost-
effective and readily administered without the need for specialized hospital equipment or travel; 





2.6 Molecular variations in intracranial neoplasms and personalized medicine 
Intuitively, as we move toward a personalized approach to therapy, we would ideally 
target molecular aberrations within the malignant cell population, preferably sparing normal 
tissues from the effects of cytotoxic therapeutics. For example, as previously stated, the addition 
of the chemotherapeutic temozolomide increases human GBM median survival time by 
approximately 2 months, but may be ineffective in some patients. Since O6-methylguanine-DNA 
methyltransferase (MGMT) is a DNA repair protein that counteracts chemotherapy-induced 
DNA damage (and specifically counteracts the alkylating effects of temozolomide), patients with 
unmethylated promoters are expected to respond poorly to temozolomide therapy.20 If an equally 
effective therapeutic alternative were available for such patients, using this regimen instead of 
temozolomide would likely improve patient survival, as those least likely to derive therapeutic 
benefit would not experience unnecessary hematopoietic toxicity.41, 42 This would be an example 
of a personalized therapeutic approach for such patients. Molecular genetic analysis is common 
in human medicine, and is being investigated increasingly in veterinary medicine as well.3, 35  
Neoplastic cell transformation is a multistep, progressive process, whereby cells acquire 
sequential mutations, eventually leading to a malignant phenotype.43 Molecular characterization 
is becoming a mainstay of therapeutic advancement in both human and veterinary oncology. It 
may allow further classification of tumors of a particular histological subtype, to help 
practitioners gain prognostic information and to aid in selecting a therapeutic regimen (as in the 






2.7 Evasion of apoptosis 
 Apoptosis is the process of programmed cell death, regulated by aspartate-specific 
cysteine proteases (caspases). Caspases are produced in cells as inactive zymogens. Initiating 
events include processes that damage the cell internally (such as DNA damage), leading to 
activation of the intrinsic apoptotic pathway, or binding of an extracellular death ligand to its cell 
surface receptor, leading to activation of the extrinsic apoptotic pathway.44 Following initiation, 
both pathways converge via an amplifying cascade of proteolytic caspase activation, ultimately 
leading to the cleavage and activation of downstream “executioner” caspases. Caspase-3 is the 
key executioner caspase that is ultimately responsible for the cleavage of many essential cellular 
components (Figure 2.4).45, 46  
In multicellular organisms, apoptosis serves a physiological function to remove infected, 
defective, or extraneous cells. In the adult, apoptosis is common in hormone-dependent tissues, 
such as the female mammary gland and endometrium.47 Evasion of apoptosis, or programmed 
cell death, is one hallmark of malignantly transformed cells as outlined by Weinberg et al.43 
Broadly, cancer cells may evade apoptosis via disrupted equilibrium of pro- and anti-apoptotic 
proteins, reduced caspase function, and impaired death receptor signaling (Figure 2.5). The most 
commonly implicated proteins include members of the Bcl-2 protein family, which are dimers 
that are responsible for outer mitochondrial membrane permeability; TP53, one of the best 
known tumor suppressor genes also known as the “guardian of the genome;” and IAPs (inhibitor 
of apoptosis proteins), which inhibit caspase proteins.45, 46  
Bcl-2 is an anti-apoptotic protein that prevents release of pro-apoptotic cytochrome-c 
from the mitochondrion via multiple mechanisms, including maintenance of the mitochondrial 
membrane and binding to pro-apoptotic members of the Bcl-2 family. Although we did not 
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specifically identify resources addressing increased expression of Bcl-2 in canine intracranial 
neoplasms, there is literature to suggest that Bcl-2 expression may be perturbed in some canine 
neoplasms. In one study of canine and human mammary tumors, there was significantly 
increased expression of PCNA (proliferating cell nuclear antigen), Bcl-2, TP53, and ER 
(estrogen receptor) as compared to normal adjacent tissues.48 Another study of canine mammary 
carcinomas suggests that ER may regulate Bcl-2 protein, as is the case in human mammary 
cancer.49 In a study of canine vascular tumors, hemangiosarcomas had increased 
immunohistochemical expression of Bcl-2.50 
TP53 is constitutively expressed in almost all cell types and is a transcription factor 
involved in cell cycle control, apoptosis, senescence, DNA repair, and maintenance of genome 
stability.51 TP53 is the most frequently altered gene in human cancer, and has been implicated in 
various types of brain tumors.24 In dogs, one study has demonstrated that genetic mutations of 
TP53 are present in astrocytomas, albeit in lower numbers than in humans; however, the 
mutations evaluated in this study may not be the cause of TP53 mutation in canine brain 
tumors.26, 52 In another study, 35% of canine astrocytomas showed increased expression of TP53 
alterations via immunohistochemistry.53  
IAPs were first discovered in baculoviruses, where they suppress host cell death 
mechanisms during viral infection. IAPs are characterized by a variable number of Baculoviral 
IAP repeat (or BIR) motifs; these BIR domains directly bind to and inhibit the proteolytic 
activity of caspases within the cell.  Members of the IAP family include survivin, ILP2, ML-IAP, 
XIAP, c-IAP1, c-IAP2, NAIP, and BRUCE.54 Although there are no specific resources that 
address the upregulation of IAPs in canine brain tumors to our knowledge, there are reports in 
the literature of various canine neoplasms that have upregulated IAPs or sensitivity to IAP 
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inhibitors. These include a study in which there was increased survivin expression in canine mast 
cell tumors;55 increased expression of survivin mRNA in a canine mammary tumor, melanoma 
and synovioma;56 and increased sensitivity to chemotherapeutics with XIAP inhibition in canine 
bile duct, mammary carcinoma, and osteosarcoma cell lines.57  
In a preliminary investigation of genetic aberrations in canine meningiomas, deleted 
chromosomal segments were syntenic to the chromosomes most often deleted in human 
meningioma, and importantly, genes that function in DNA repair, cell cycle progression, and 
apoptosis are located on these deleted chromosomal segments.17 
 
2.8 PAC-1 restores apoptosis in cells with disordered apoptotic pathways 
There are numerous existing therapeutics that target aberrant apoptotic pathways in 
cancer cells, including molecular disruptors of TP53-MDM2, inhibitors of Bcl-2, and ligands for 
XIAP.58 As both the intrinsic and extrinsic apoptotic pathways ultimately converge on activation 
of the executioner caspases (caspase-3 and caspase-7), direct activation of the executioner 
caspases would bypass abnormal upstream apoptotic circuitry, regardless of the specific 
upstream perturbation present. Professor Paul Hergenrother’s laboratory reported the discovery 
of PAC-1 (first procaspase-activating compound), a small molecule, pro-apoptotic, and blood-
brain-barrier penetrant drug, in 2006.23 PAC-1 induces apoptosis in a target-dependent fashion, 
with cells expressing higher levels of PC-3 being more sensitive to apoptotic cell death. Since 
PC-3 levels are elevated in many tumor types, including high-grade glial tumors, this confers a 
selective therapeutic target, in which PAC-1 may be able to induce cell death in malignantly 
transformed tissue while sparing normal tissues from these effects.59 On a molecular level, PAC-
1 works by chelating labile zinc ions, which are typically auto-inhibitory to PC-3.60 Extensive 
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pharmacokinetic and tolerability studies were previously performed by our group at the 
University of Illinois, and we have identified safe and well-tolerated oral doses of PAC-1 that 
can be administered chronically and do not elicit significant side effects. Pet owners have 
reported a mild and reversible change in personality and occasionally mild pelvic limb ataxia 





MATERIALS AND METHODS 
3.1 Cell lines 
 Five glioma cell lines were used in this study. Three canine glioma cell lines, SDT-3g, 
GO6A, and J3T-Bg, were provided by Professor Peter J. Dickinson, University of California. 
U118 was purchased from ATCC (American Type Culture Collection, Manassas, VA) and 
GL261 was provided by Professor Edward J. Roy, University of Illinois. The IOMM-Lee and 
KT21-MGT human meningioma cell lines were provided by Professor Paul J. Hergenrother, 
University of Illinois. Cells were cultured at 37 degrees Celsius in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with penicillin (100 IU/mL), streptomycin (100 IU/mL), and 
10% fetal bovine serum in a humidified atmosphere supplemented with 5% CO2. Cell cultures 
were maintained in subconfluent monolayers and passaged two to three times weekly as needed.  
 
3.2 Antibodies 
 Antibodies and their manufacturers, isotypes, pretreatments, dilutions, and times of 
application are provided in Table 3.1. Antibodies were purchased from the listed manufacturer, 
or were provided by Dr. Stéphane Lezmi (formerly at the University of Illinois, now at Ipsen 
Pharmaceuticals in Paris, France).  
 
3.3 Neurosphere culture 
 GL261 neurospheres were cultured at 37 degrees Celsius in Dulbecco’s Modified Eagle’s 
Medium-F12 (DMEM-F12) with Glutamax, 2% Vitamin B27 Supplement (Gibco, Thermo 
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Fisher Scientific, Waltham, MA), FGF (20 ng/mL) and EGF (20 ng/mL). Cell cultures were 
maintained in subconfluent monolayers and passaged two to three times weekly as needed.  
 
3.4 Cell protein collection 
 Cells were grown in culture until 80-100% confluent in a monolayer. Media was removed 
and cells were washed with phosphate-buffered saline (PBS). Cells were exposed to 2 mL 
trypsin for five minutes to detach them from the culture plate, followed by addition of 4 mL 
media to neutralize the effects of trypsin. Collected cells were centrifuged at 1,500 rpm at 4º C 
for 5 minutes. The trypsin/media supernatant was removed, and the cell pellets were resuspended 
in 1 mL PBS and transferred to a 1.5 mL Eppendorf tube. Cells were centrifuged at 10,000 rpm 
at 4º C for 5 minutes. The PBS supernatant was discarded. Cell pellets were homogenized with 
100 µL of Mammalian Protein Extraction Reagent (abbreviated as M-PER, Pierce, Rockford, 
IL), then mixed with fresh Pierce protease inhibitor cocktail solution (diluted 1:100 for final 
working solution). The homogenate was placed on a shaker for 15 minutes at room temperature. 
Cellular protein concentrations were determined using a standard assay kit (Bicinchoninic Acid 
Protein or BCA, Pierce, Rockford, IL).  
 
3.5 Tissue protein collection 
 Tissues were collected from previously euthanized shelter dogs as part of the Tissue 
Harvesting program at the University of Illinois. Brains were collected within 5 hours of death 
from twenty-one dogs with no prior history of overt systemic illness.  Sections of the cerebral 
cortex, hippocampus, cerebellum, and brain stem were taken from each dog (Figure 3.1); 
samples from each anatomic area were placed in 10% buffered formalin and were flash frozen 
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with dry ice in each case. Frozen samples were stored at -80 degrees Celsius until analysis could 
be performed. Small sections of frozen tissue were weighed and then added to a 5 mL Eppendorf 
tube with Tissue Protein Extraction Reagent (abbreviated as T-PER, Pierce, Rockford, IL) at a 
ratio of ~1g of tissue per 10 mL T-PER. Tissue was manually homogenized. The tissue sample 
was placed on a shaker for 15 minutes at room temperature. The sample was centrifuged at 
10,000 rpm for 5 minutes. The supernatant was collected and used to determine protein 
concentration using a standard assay kit (Bicinchoninic Acid Protein or BCA, Pierce, Rockford, 
IL).   
 
3.6 Western Blot analysis 
 For evaluation of PC-3 expression, 50 µg samples of cells were electrophoresed on 12% 
polyacrylamide gel, then transferred electrophoretically to a nitrocellulose membrane. Beta Actin 
(Abcam #ab6276-100, Cambridge, MA) was used as a loading control. Band intensity was 
measured in Image Lab computer software (BioRad Laboratories, Inc., Version 6.0.0 build 25, 
Des Plaines, IL).  
 
3.7 Immunohistochemistry 
Formalin-preserved samples were fixed for 24 hours, and were then paraffin-embedded.  If 
sample collection occurred such that paraffin embedding could not occur in the following 24 hours, 
the formalin was diluted 50% with PBS until this could occur on the next available business day.   
Immunohistochemical (IHC) staining was performed using an indirect 
immunoperoxidase technique with diaminobenzidine (DAB) as the chromogen for PC-3, 
caspase-3 (C-3), and isotype controls (GAD67 and Calbindin-D-28K).  For these antibodies, IHC 
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staining was performed using an autostainer (intelliPATH FLX, Biocare, Concord, CA).  
Processed slides were deparaffinized in xylene and rehydrated in alcohol.  Endogenous 
peroxidase activity was blocked with Biocare #PX968 Peroxidazed 1 at room temperature for 5 
minutes, rinsed with TBS wash buffer, and then incubated for 10 minutes at room temperature 
with Biocare #BP974 Background Punisher.  Slides were incubated with PC-3 antibody (Abcam 
#ab32150) for 39 minutes at a dilution of 1:3000, washed, and then incubated with Rabbit-on-
Canine HRP-Polymer (Biocare #RC542) for 30 minutes.  Slides were washed in TBS wash 
buffer.  The reaction was developed using DAB substrate for 5 minutes and the slides were then 
counterstained with Mayer’s hematoxylin.  A section of canine lymph node served as negative 
and positive control.  
Additionally, canine tissue with moderately intense PC-3 staining was further evaluated 
using double fluorescent staining, in which PC-3 or caspase-3 staining was coupled with 
doublecortin, NeuN, or GFAP. Slides were deparaffinized in xylene twice for 5 minutes. They 
were rehydrated with 100% ethanol, twice for 3 minutes, and once with 95% ethanol for 1 
minute. The slides were rinsed in distilled water prior to receiving pre-treatment, as outlined in 
Table 3.1. Slides were rinsed in PBS-Tween 20 two times for 2 minutes. Slides were blocked 
with 1% BSA and incubated with both primary antibodies for one hour at room temperature. 
Slides were rinsed in PBS-Tween 20 twice for 3 minutes. Slides were incubated with secondary 
fluorescent antibodies in PBS for 30 minutes, then rinsed in PBS-Tween 20 twice for 3 minutes. 
Slides were counterstained with DAPI for 20 minutes at room temperature, then rinsed in PBS-
Tween 20 twice for 2 minutes. Slides were cover-slipped with anti-fade fluorescent mounting 
medium. A section of canine lymph node was used as a negative and positive control in these 
samples. Slides were imaged with a Zeiss LSM 700 confocal microscope (Dublin, CA).  
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Antibodies and their manufacturers, isotypes, pretreatments, dilutions, and time of 
application are listed in Table 3.1.  
 
3.8 Scoring of immunoreactivity data 
Three canine glioma microarrays (courtesy Dr. Peter J. Dickinson, University of 
California at Davis), six human microarrays (MG801a, GL2082, and GL2083a, US Biomax, 
Inc., Rockville, MD and three microarrays, courtesy of Dr. Charles Eberhart, Johns Hopkins 
University, Baltimore, MD), and 32 archived samples (26 canine meningiomas, 6 canine 
astrocytomas) from the University of Illinois Veterinary Diagnostic Lab were evaluated for PC-3 
immunostaining using ab32150 (Abcam, Cambridge, MA).  Samples were assigned a numerical 
designation, and a random number generator was used to select each sample prior to evaluation.  
500 cells from each sample (when available) were graded by one observer (LJS) on a continuous 
grading scale, and the percentage of negative, faintly staining, moderately staining, and strongly 
staining cells were recorded (Figure 3.2). Negatively staining samples contained <10% positive 
cells. Cells that had <50% cytoplasmic staining were graded as “faintly staining,” those with 
>50% cytoplasmic staining were graded as “moderately staining,” and those with >50% 
cytoplasmic staining and in which nuclear detail was obscured by the staining intensity were 
categorized as “strongly staining.” If 500 cells were not available for grading, all available cells 
were used to determine the relative immunostaining properties of cells within the sample.  
Manual grading was repeated three times for each sample to ensure consistency; although cell 
percentages differed slightly between observations for the same tumor, the final manual tumor 
grade was the same in each case.  Canine microarray samples were secondarily evaluated using 
the iCyte automated imaging cytometer (Model TLC 1413, ThorLabs, Newton, NJ).  The iCyte 
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is a laser-scanning microscope that combines digital imaging with real time population data 
analysis of analytical cytometry; in addition to detecting fluorescence, the iCyte is able to detect 
and quantify the amount of diaminobenzadine (DAB) chromogen staining present within the 
sample (manufacturer’s user manual data).  Gates for faintly staining, moderately staining, and 
strongly staining cells were established using criteria established during manual grading. When 
there were multiple cores of tissue available for a single case, the mean percentages of faintly, 
moderately, and strongly positive cells were used (both for manual and iCyte grading) to 
determine a final grade for the sample. Normal tissue was used to establish the threshold between 
negatively and positively staining tumor samples.  Raw grading scores were determined using 
the following formula:  
1 ×  (% 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑝𝑝𝑝𝑝𝑝𝑝𝑓𝑓𝑓𝑓𝑓𝑓𝑝𝑝𝑝𝑝 𝑐𝑐𝑝𝑝𝑓𝑓𝑓𝑓𝑝𝑝) + 2 × (% 𝑚𝑚𝑝𝑝𝑚𝑚𝑝𝑝𝑚𝑚𝑓𝑓𝑓𝑓𝑝𝑝𝑓𝑓𝑓𝑓 𝑝𝑝𝑝𝑝𝑝𝑝𝑓𝑓𝑓𝑓𝑓𝑓𝑝𝑝𝑝𝑝 𝑐𝑐𝑝𝑝𝑓𝑓𝑓𝑓𝑝𝑝) + 3 × (% 𝑝𝑝𝑓𝑓𝑚𝑚𝑝𝑝𝑓𝑓𝑠𝑠𝑓𝑓𝑓𝑓 𝑝𝑝𝑝𝑝𝑝𝑝𝑓𝑓𝑓𝑓𝑓𝑓𝑝𝑝𝑝𝑝 𝑐𝑐𝑝𝑝𝑓𝑓𝑓𝑓𝑝𝑝) 
PC-3 immunostaining grades were assigned based on natural numeric cutoffs observed following 
use of this formula, and tumors were categorized as negative for scores <10, grade 1 - faintly 
staining for scores <50, grade 2 - moderately staining for scores <150, or grade 3 - strongly 
staining overall with scores >150.   
 
3.9 Statistical analysis of PC-3 IHC inter-observer variability  
Inter-observer variability was estimated with a Kappa statistic by comparing the 
automated grades generated by the iCyte automated imaging cytometer with manual visual 
grades.   
 
3.10 Colony Forming Assays 
 All colony forming assay experiments were performed over 14 days with a 5 day 
treatment, 2 day rest schedule to most closely mimic a clinical scenario. All cells were allowed to 
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attach to cell culture plates at least 24 hours prior to treatment. For all experiments in which 
PAC-1 therapy was evaluated, a DMSO vehicle control column, corresponding to the volume of 
DMSO present in the highest PAC-1 concentration, was used to ensure observed cytotoxicity 
was not due to DMSO alone. Two methods were employed for colony forming assays for this 
project.  
Since we initially wanted to evaluate a large range of PAC-1 doses in many different cell 
lines, we initially utilized a high throughput colony forming assay, as described by Katz et al.61 
50 GL261, GO6A, SDT3g, U118-MG, IOMM-lee, and ~10 J3T-Bg cells were seeded in 100 µL 
of complete media in 96-well plates. Cells were treated with 4-hour, 8-hour, and 12-hour pulse 
PAC-1 therapy at doses ranging 0.1 to 300 µM. Following the 14-day experimental period, cells 
in the high throughput CFA group were stained with 5 µM Hoescht 33342 and 10 µM Cell 
Tracker Orange CMTMR. Cells were counted automatically using the iCyte automated imaging 
cytometer (Model TLC 1413, ThorLabs, Newton, NJ). The number of colonies per well was 
manually determined by counting aggregates of >50 cells.  
Cell viability was also assessed using a CellTiter Blue assay (Promega, Fitchburg, WI). 
CellTiter Blue is based on the ability of living cells to convert a redox dye (resazurin) into a 
fluorescent end product (resofurin), which can be measured by a fluorescent plate reader. 50 
GL261, 50 U118-MG, and ~10 J3T-Bg cells were seeded in 100 µL of complete media in 96-
well plates. Cells were treated as above on a 5 day treatment, 2 day off schedule, with 4-hour, 8-
hour, and 12-hour pulse PAC-1 therapy at doses ranging 0.1 to 300 µM. Following the 14-day 
study period, cell viability was assessed with the CellTiter Blue reagent and readout from the 
fluorescent plate reader.  
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The traditional colony forming assay was performed using 6-well plates and murine 
(GL261), canine (J3T-Bg), and human (U118-MG) glioma cell lines. 200 GL261 and U118-MG 
cells and 30 J3T-Bg cells were seeded in 2 mL of complete media in 6-well plates. Initially, 
effects of radiation therapy (RTH) alone were assessed to determine IC50 doses. Cells were 
exposed to no RTH, 0.1 Gy, 0.3 Gy, 1 Gy, and 3 Gy for 10 doses. At the end of the experiment, 
cell plates were stained and fixed with glutaraldehyde 6% (v/v) and crystal violet 0.5% (wt/vol) 
in water. The number of cell colonies with >50 cells was counted manually using a phase-
contrast stereomicroscope.  
Next we wanted to evaluate combination PAC-1 and radiation therapy (RTH) in 
immortalized glioma cell lines. This experiment was performed using a traditional 6-well colony 
forming assay. Cells were treated for 10 days on a 5 day treatment, 2 day off schedule to mirror a 
clinical scenario. Cells were treated with DMSO vehicle control, 0.3 µM, 0.1 µM, or 3 µM PAC-
1 dissolved in DMSO for 6 hours. Following PAC-1 or vehicle therapy, cells were rinsed with 
PBS and fresh media was added. RTH was performed one hour after adding PAC-1 to cell 
culture, to maximize apoptotic cell death. The number of cell colonies with >50 cells was 
counted manually using a phase-contrast stereomicroscope. 
In all cases, dose-response curves and IC50 determinations were performed with Origin 
software. Synergism between PAC-1 and RTH was determined with Combenefit software and 





3.11 Stereotactic implantation of syngeneic GL261 cells into the right cerebral hemispheres of 
C57BL/6 mice 
All animal procedures were approved by the University of Illinois IACUC (Institutional 
Animal Care and Use Committee). 8-week-old female intact C57BL/6 mice were obtained from 
Charles River. Mice were allowed to acclimate to their new environment at least 7 days prior to 
cell implantation. The day prior to surgery, mice were anesthetized using 2-3% isoflurane in an 
induction chamber, then were maintained on 1.5-2% continuous flow isoflurane via a nose cone. 
A ~1 cm square area was shaved caudal to the orbit and just to the right of midline in preparation 
for surgery. A small amount of Nair hair removal cream was used to remove residual fur. On the 
day of surgery, media containing non-adherent neurospheres was collected. To maximize cellular 
yield, cells were exposed to trypsin for 5 minutes to detach them from the culture plate, followed 
by the addition of media to neutralize the effects of trypsin. Collected cells were centrifuged at 
1,500 rpm at 4 deg C for 5 minutes. The trypsin/media supernatant was removed, and the cell 
pellets were resuspended in a small amount of media. A small sample of these cells were stained 
with Trypan-blue solution and enumerated with a hemacytometer to determine the number of 
cells per unit volume of media in the sample. Cells were washed twice with Hanks Balanced Salt 
Solution (HBSS), then suspended in a solution of 50,000 cells/0.5 µL and placed on ice. Mice 
were induced and anesthetized as previously described. To complete cell implantation, a 5 mm 
incision was made slightly to the right of midline and just caudal to the orbit. A Stereotaxic unit 
was used to place the cellular implantation site +0.55 mm anterior and 2.5 mm to the right of the 
Bregma. The skull was punctured using a 27g needle mounted on the Stereotaxic holder. A 0.5 
µL Hamilton syringe with a 33g needle was advanced -3.5 mm ventral to the skull surface. Cells 
were injected over a period of 1 minute, and two minutes were given to allow back pressure to 
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dissipate. The syringe was slowly raised over 30 seconds. The incision site was closed with a 
small drop of VetBond. Mice were placed in individual clean cages to allow the incision sites to 
heal.  
 
3.12 PAC-1 therapy in tumor-bearing mice 
Tumor-bearing mice received 10 doses of PAC-1 over two weeks. Following 
implantation of GL261 cells in the right cerebral hemisphere at least 24 hours prior, mice either 
received 100 mg/kg PAC-1 in HPβCD vehicle or HPβCD vehicle control via oral gavage once 
daily for 10 doses (administered on a 5 day treatment, 2 day off schedule to mirror 
administration of therapy that would occur in a hospital setting). When mice began to experience 
neurological clinical signs consistent with compression from tumor growth (generally manifested 
as circling in one direction, head-pressing in the corner of the cage, tremoring or ataxia), the 
mice were humanely euthanized with CO2, as outlined in the American Veterinary Medical 
Association’s guidelines for humane euthanasia.64 A Kaplan-Meier curve was performed to 
assess survival using Origin software. 
 
3.13 PAC-1 and radiation therapy in tumor-bearing mice 
For this phase of the study, there were four groups of mice overall: those receiving PAC-
1 therapy only, those receiving radiation therapy only, those receiving combination PAC-1 and 
radiation therapy, and those receiving sham therapy (HPβCD vehicle control only). Mice were 
imaged with MRI at day 10 following GL261 tumor implantation, and tumor volumes were 
calculated with ImageJ software. Mice were divided equally into four groups, and a one-way 
ANOVA was performed to ensure that starting tumor volumes were not statistically significant 
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among groups. The mice then received 10 days of PAC-1 or sham therapy prior to a follow-up 
MRI on day 29 post-implantation. There were four groups of mice: one that received HPβCD 
vehicle control every 12 hours via oral gavage, one that received PAC-1 in HPβCD vehicle every 
12 hours via oral gavage, one that received both PAC-1 therapy via oral gavage every 12 hours 
and daily 1 Gy radiation therapy, and one group that received daily 1 Gy radiation therapy alone.  
For radiation therapy, mice were immobilized with a single 100 mg/kg intraperitoneal 
(IP) injection of ketamine and xylazine. Mice received oral medications (PAC-1 or vehicle 
control) one hour prior to radiation therapy. The radiation collimator was adjusted for full-head 
radiation therapy (RTH) with a Cobalt unit. Mice received a single 1 Gy fraction of RTH every 
24 hours for 10 doses (a total of 10 Gy). RTH was administered on a 5 day treatment, 2 day off 
schedule as described for PAC-1 therapy. Mice recovered from sedation uneventfully following 
each RTH session.  
Following MRI imaging at day 29, the tumor volume and tumor fold growth were 
calculated using ImageJ software. Mice were humanely euthanized and brains were preserved in 
10% buffered formalin. Histopathology was performed to confirm tumor implantation and 
correlate the histologic features of each tumor with its respective MRI image.  
 
3.14 Magnetic resonance imaging (MRI) 
Mice in the second phase of this study (as discussed in part 3.12) had magnetic resonance 
imaging (MRI) performed at days 10 and 29 after GL261 cell implantation. Mice were 
anesthetized in an induction chamber with 2-3% isoflurane, then were transferred to the EZ-
Anesthesia system with continuous 1.5% isoflurane in a heated chamber. Data was acquired on a 
vertical bore imaging scanner (Oxford Instruments, Abington, UK) equipped with a Unity/Inova 
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console (Varian, Palo Alto, CA), operating at 14.1 T and dedicated to small animal studies. The 
14.1T Varian microimaging system consists of a vertical wide bore magnet (89mm) and a 600 
MHz Varian Unity/Inova NMR spectrometer equipped with four identical receiver channels and 
gradient coils with maximum strength of 95 Gauss/cm. The maximum in-plane imaging 
resolution can reach 10 microns. The maximum usable magnet diameter is 30 mm. A recently 
patented radiofrequency coil and holder, specifically designed for mouse brain MRI/MRS, was 
employed to make experimental studies more informative and efficient (B.Odintsov “Tunable 







4.1 PC-3 is expressed in a predictable anatomic pattern in the normal canine brain 
 A predictable and consistent PC-3 immunostaining pattern was observed in all normal 
canine brains. In the five anatomic regions sampled, PC-3 expression appeared strongest in the 
hippocampus, particularly in the dentate gyrus and in the cerebral cortical gray matter. There was 
less intense immunostaining in the brain stem and cerebellum. Although the staining pattern in 
these various anatomic areas was consistent among the dogs sampled, there was mild individual 
variation in the PC-3 immunostaining intensity. Figure 4.1 shows representative images of brains 
from three dogs with individual stain intensity variation. Figure 4.2 shows representative images 
of four distinct anatomic regions. PC-3 appeared to be most strongly expressed in synaptic fibers 
and in some neurons. Immunoblotting using flash-frozen sections of canine brain with beta actin 
control corroborated these findings (Figure 4.3).  
 
4.2 Low numbers of neurons and many synaptic fibers overexpress PC-3 normally 
 All antibodies evaluated for PC-3 and Caspase-3 (C-3) staining showed similar staining 
patterns in the normal canine brain (Figure 4.4 and 4.5). These proteins are expressed in neurons, 
and consistently in synaptic fibers throughout the normal canine brain. Isotype, positive, and 





4.3 PC-3 is overexpressed in a small panel of canine tumors 
 In 32 cases of primary brain tumors from archived cases at the University of Illinois 
Veterinary Diagnostic Laboratory, 87.5% (28/32) of tumors overexpressed PC-3 relative to the 
normal brain tissue obtained from cadaver dogs. Figure 4.6 shows three representative cases of 
the most common brain tumor histologies in pet dogs (astrocytoma, oligodendroglioma, and 
meningioma), which contain normal tissue adjacent to neoplastic tissue. In each case, the tumor 
tissue stains more intensely for PC-3 than the adjacent normal tissue.  
 
4.4 PC-3 is overexpressed in most human and canine intracranial neoplasms 
 In 174 canine tumors and 496 human tumors, PC-3 is overexpressed relative to normal 
brain tissue. Specifically, 83% of canine astrocytomas and 62% of human astrocytomas 
overexpress PC-3. Within this subset of tumors, low histologic grade astrocytomas (pilocytic 
grade I and grade II tumors) had less PC-3 expression as compared to high histologic grade 
astrocytomas (Figure 4.7). 92% of canine and 70% of human meningiomas overexpress PC-3 
(Figure 4.8). 73% of canine and 70% of human oligodendrogliomas overexpress PC-3 (Figure 
4.9).  
 
4.5 Kappa statistic for iCyte versus manual grading 
 A Kappa statistic, which measures interobserver variation, was >0.81 for both human and 
canine samples, consistent with almost perfect agreement65 between manual and iCyte automated 
cytometer tumor grading. For canine samples, Kappa = 0.88 (95% confidence interval: 0.84-
0.92), and for human samples, Kappa = 0.92 (95% confidence interval: 0.89-0.95). For all 
samples considered, Kappa = 0.90 (95% confidence interval: 0.88-0.93).  
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4.6 Immortalized canine, human, and murine glioma cell lines express PC-3 
 Immunoblotting analysis demonstrated expression of a 32 kDa single or occasionally 
double band (two canine cell lines), consistent with PC-3 (Figure 4.10).  
 
4.7 Glioma and meningioma cells are sensitive to PAC-1 therapy 
 In an initial in vitro PAC-1 sensitivity study, cells were treated with 0.1-100 µM PAC-1 
with 4-hour pulse therapy over a 2-week period (10 treatments, given on days 1-5 and 8-12). 
Figure 4.11 shows that five glioma cell lines (one murine, one human, and three canine) and one 
human meningioma cell line are sensitive to PAC-1 monotherapy when administered in this 
fashion.  
 
4.8 Glioma cell lines are sensitive to radiation therapy (RTH) and combination RTH and PAC-1 
therapy 
 Three glioma cell lines (one murine, one canine, and one human) were selected for 
further characterization. All three cell lines are sensitive to both PAC-1 and RTH monotherapies, 
and in all three cell lines, there is calculated synergism when these two therapies are combined, 
leading to greater cytotoxicity than that observed with either monotherapy alone (Figures 4.12, 
4.13, 4.14, and 4.15). In both the murine and human cell lines, nearly 100% cell death is 
achieved in vitro with biologically achievable doses of both PAC-1 and radiation therapy. The 
IC50 values for all cell lines evaluated are listed in Table 4.1.  
The selected murine and human cell lines were more sensitive to therapy than the canine 
cell line. When we evaluate our Western blot for PC-3 expression in these cell lines (Figure 
4.10), we observe that the canine cell line has lower expression of the drug target relative to the 
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murine or human cell lines; this may explain, in part, its higher resistance to PC-3 therapy. 
Relative to the other canine glioma cell lines, J3T-Bg also has the highest IC50 for PAC-1 pulse 
therapy (29.8 µM versus 0.16 µM for GO6A or 14.7 µM for SDT-3g), indicating greater 
resistance to PAC-1. 
 
4.9 Orthotopically implanted gliomas appear to be sensitive to PAC-1, radiation therapy, and 
combination therapy with both agents 
 50,000 GL261 syngeneic neurosphere-cultured cells were injected into the right cerebral 
hemispheres of C57/BL6 mice. Figure 4.16 shows a schematic representation of the area of the 
brain in which tumor cells were injected,66 as well as an image of a mouse brain from this study 
with the engrafted tumor. Within the tumor histopathology in each case, the cells were markedly 
pleomorphic. Each histopathological section showed cells with numerous mitotic figures, 
multinucleated cells, moderate to marked anisokaryosis and anisocytosis, and frequent 
karyomegaly. Large, central areas of necrosis were common within the central areas of these 
tumors. Following 10 doses of oral therapy with 100 mg/kg PAC-1, mice were observed for 
neurological signs and their median survival times were calculated. Mice that did not receive 
PAC-1 had a median survival time (MST) of 39.9 days, while mice receiving PAC-1 had a MST 
of 52 days. These results were not statistically significant with a log-rank test (p = 0.39 at α = 
0.05). Figure 4.17 shows a Kaplan-Meier plot of these data.  
 In the second arm of this study, evaluating PAC-1 therapy with radiation therapy, 50,000 
GL261 syngeneic neurosphere-cultured cells were injected into the right cerebral hemispheres of 
C57/BL6 mice. 10 days post-injection, brains of these mice were imaged with magnetic 
resonance imaging (MRI). Following treatment with PAC-1, radiation therapy, combination 
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therapy, or PAC-1 vehicle control, animals were imaged again with MRI and were humanely 
euthanized. Figure 4.18 shows that there is evidence of tumor growth between day 10 and day 29 
in each group of animals studied. While the results were not statistically significant with a one-
way ANOVA testing differences among mean tumor volume (p = 0.94 at α = 0.05) and tumor 
fold increase (p = 0.21 at α = 0.05) among treatment arms, there was a promising trend observed, 
in which the animals receiving radiation or PAC-1 monotherapy had reduced tumor volume as 
well as tumor fold increase over the course of the study (Figure 4.19). One mouse that had 
received combination PAC-1 and radiation therapy had a well-defined tumor at 10 days post-
injection as imaged by MRI, but had no MRI or histopathological evidence of a tumor at day 29 
(Figure 4.20). Histopathological evaluation of these tumors was consistent with successful tumor 




DISCUSSION AND CONCLUSIONS 
In normal canine brain tissue, PC-3 staining was observed at low levels in neurons and in 
synaptic fibers. Programmed cell death is an important process in the developing nervous system 
that results in optimization of synaptic connections and removal of unnecessary neurons.67 This 
vital role of caspase-3 in homeostatic apoptosis is obvious in some strains of caspase-3 deficient 
mice, in which protrusions of neural tissue result in skull defects, there is obstruction of cells, 
and there are foci of ectopic cells, all leading to embryonic death.68 A recent review article by 
D’Amelio et al highlights the non-apoptotic roles of caspase-3, which explain its synaptic 
staining pattern within the brain.67  While studying the effects of caspase-3 deficiency in 
Caspase-3 -/- C57BL/6 mice, Lo et al inadvertently found that caspase-3 is important in cognition 
and behavior, particularly inhibitory control, and that it is a key player in synaptic homeostasis.69 
Activated caspase-3 is in the postsynaptic terminal of neurons in the auditory forebrain of the 
zebra finch, and that caspase-3 is necessary for long-term habituation to a new song in this 
species.70 Additionally, caspase-3 appears to be necessary for long-term plasticity in neurons of 
the terrestrial snail, Helix lucorum.71 
In previous work by our group, the effect of PAC-1 treatment on the normal brain was 
assessed in healthy male and female C57BL/6 mice, who received an oral dose of PAC-1 in 
aqueous suspension of 50 mg/kg every 24 hours for 14 days.  These mice had no evidence of 
neuroexcitation, behavioral change, or histological evidence of inflammation or cellular injury.  
Importantly, cleaved caspase-3 staining was not present within neuronal cell bodies.72 These 
findings indicate that although cellular activation of PC-3 occurs secondary to PAC-1 
administration in neoplastic cells, there is no evidence of perturbation in normal cells leading to 
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behavioral impairment or histologic change.  Additionally, administration appears to be well-
tolerated in mice, both in this study and previously.   
In both our archived necropsy and biopsy specimens at the University of Illinois, as well 
as in multiple tissue microarrays, PC-3 appeared to be overexpressed in most intracranial 
neoplasms, both in canine and human tissue. Importantly, in the available necropsy samples of 
canine tissue in which there were directly comparable normal and malignantly transformed 
tissues, PC-3 immunostaining was more intense in the tumor tissue. In one oligodendroglioma 
sample, intact hippocampal tissue was present. As this is the area of greatest PC-3 
immunostaining intensity in the normal canine brain, the greater degree of PC-3 staining in this 
patient’s tumor tissue implies a druggable target for apoptosis in canine intracranial neoplasms. 
In evaluation of approximately 700 canine and human astrocytomas, PC-3 immunostaining 
intensity was greater in tumors with higher histologic grade (Grade III astrocytomas and 
Glioblastoma multiforme); this indicates that both human and canine patients who have the most 
dire clinical prognoses may benefit most dramatically from PAC-1 therapy.  
Immunohistochemical PC-3 findings were corroborated by measurements made using the 
iCyte automated imaging cytometer. Inter-observer variability was calculated with the Kappa 
statistic, and found to be nearly perfect for all observations. In cases in which there was not 
agreement between manual and automated grading, there were identifiable features of these 
tissues that likely led to the observed disagreement. These factors included focal necrosis, in 
which PC-3 staining appeared more intense to the automated cytometer than during manual 
grading; PC-3 staining of non-tumor components, including endothelial cells, which were 
counted as positively staining tumor cells by the automated cytometer; and focal areas of missing 
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tissue in tumor cores that were mistakenly counted as “poorly staining” by the automated 
cytometer.  
Immunoblotting analysis confirmed that PC-3 is expressed consistently as a 32 kDa band 
in one murine, three canine, and two human glioma cell lines. Of these cell lines, one murine, 
one canine, and one human glioma cell line were further characterized. All three cell lines were 
found to be sensitive to both PAC-1 and radiation therapy monotherapies, as well as combination 
therapy with both agents. Although cytotoxicity was not as dramatic in the J3T-Bg (canine) cell 
line, there was calculated synergism of PAC-1 and RTH for this cell line. Doses of up to 10 µM 
are well-tolerated in patients, and further evaluation of combination therapy including higher 
doses of PAC-1 may produce more dramatic results. Significantly, PAC-1 monotherapy with the 
4-hour pulse experiment suggests that both GO6A and SDT-3g are expected to have greater 
susceptibility to PAC-1, and combination experiments with RTH are recommended to more fully 
characterize the responses of canine glioma cell lines to these therapies. Overall, these data were 
promising for development of an in vivo murine model.  
In both murine experiments in this study, we successfully induced gliomas in the 
intended location within the right cerebral hemisphere, as confirmed by histopathology. In the 
first part of our study, in which we studied responses to PAC-1 monotherapy, there was 
prolonged survival in mice receiving PAC-1, although these results were not statistically 
significant. In the latter study with imaging and radiation therapy, both tumor volume and tumor 
growth appeared to be decreased for all therapeutic arms relative to control. Although these 
results were not statistically significant, they suggest that PAC-1 as a single agent and as a part 
of combination therapy may provide a therapeutic benefit. Additional studies more fully 
characterizing this murine model, both alone and in combination with other therapeutic 
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modalities, is warranted, given these initially promising data and the immunohistochemical PC-3 









Figure and Figure Legend Source, parts A-G: Purves D, Augustine GJ, Fitzpatrick D, et al., 
editors. Neuroscience. 2nd edition. Sunderland (MA): Sinauer Associates; 2001. Neuroglial 
Cells. Available from: https://www.ncbi.nlm.nih.gov/books/NBK10869/ 
Images above figure: 400x images from a canine astrocytoma (left) and oligodendroglioma 
(right), placed above their cells of origin, hematoxylin and eosin stain. Neuroglial cells. Tracings 
of an astrocyte (A), an oligodendrocyte (B), and a microglial cell (C) visualized by impregnation 
with silver salts. The images are at approximately the same scale. (D) Astrocytes in the brain 
labeled with an antibody against the astrocyte-specific protein (glial fibrillary acidic protein). (E) 
A scanning electron micrograph of a single oligodendroglial cell imaged in tissue culture. (F) A 
peripheral axon ensheated by the processes of Schwann cells (in green), except for at a distinct 
region called the node of Ranvier (labeled in red). (G) A microglial cell from the spinal cord, 




















Figure 2.2 illustrates the meninges, the three protective layers covering the brain, brain stem, and 
spinal cord: dura mater, arachnoid mater, and pia mater. Meningiomas arise from the arachnoid 
cap cells of the arachnoid mater. The added histopathology image is a 400x view of a canine 
meningioma, hematoxylin and eosin stain.  
 
Image source:  
 
Purves D, Augustine GJ, Fitzpatrick D, et al., editors. Neuroscience. 2nd edition. Sunderland 








Figure 2.3 illustrates the physical differences between normal blood capillaries and those in the 
brain.  
 
Source: Deeken JF, Löscher W. The blood-brain barrier and cancer: Transporters, treatment, and 







The apoptotic cascade.  
 
Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 
2011;30(1):87. doi:10.1186/1756-9966-30-87. The yellow arrow indicates the molecular site of 








Mechanisms of apoptotic evasion. 
 






Table 3.1, summarizing antibodies used for this study 
Table 3.1 
Antibody Manufacturer Host & 
Isotype 
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Figure 3.1 illustrates the brain sections that were sampled from each dog for Western blot and 








Representative illustrations and images to demonstrate cell grading criteria.  A and B: Negative 
cells contained no overt cytoplasmic staining for PC-3 antibody; faintly positive cells had <50% 
cytoplasmic staining; moderately positive cells had at least 50% positive cytoplasmic staining; 
and strongly positive cells had extensive cytoplasmic staining that obscured at least some nuclear 
detail in the cell.  C: Representative images of meningioma samples (top row) and astrocytoma 
tissue microarray cores (bottom row) that were graded following evaluation of 500 cells for 
criteria outlined in A and B.    
  
Negative Faintly + Moderately + Strongly + 






Figure 4.1  
A: areas sampled in each brain. B: PC-3 immunostaining in three representative normal canine 











Representative normal PC-3 immunostaining in canine tissue. A: Brain stem, B: Cerebellum, C: 
Cerebral cortical gray matter, D: Cerebral cortical white matter, E: Dentate gyrus, hippocampus. 










Figure 4.3  
Representative Western blot images from normal canine brains and band intensity quantification 
as measured by ImageJ software. Cb: cerebellum, WM: cortical white matter, GM: cortical gray 
matter, BS: brain stem, HC: hippocampus, LN: control lymph node. Expression of protein at 32 






PC-3 and Caspase-3 antibodies show similar patterns of anatomic expression in the cerebellum, 
cerebrum, hippocampus, and brain stem of the normal canine brain. A: Abcam #ab32150, PC-3 
only; B: Abcam #ab17868, Caspase-3; C: Abcam #ab13585, Cleaved Caspase-3; D: Abcam 





PC-3 or Caspase-3 is green in all images.  A: hippocampus with doublecortin (red), B: cerebral 
cortical gray matter with NeuN (red), and C: cerebellum with GFAP (red).  There is positive 







Representative images of canine brain tumors. The red overlay in image shows the area of the 
tissue occupied by the tumor, whereas the adjacent normal tissue is not colorized. Note that the 
tumor tissue has more intense PC-3 (brown) staining. The enlarged images on the right show 
tumor tissue in greater detail. A: astrocytoma, B: oligodendroglioma, C: meningioma. 
Hematoxylin and DAB, 100x (left) and 400x (enlarged images). Bottom image: Higher 
magnification of the normal hippocampus and tumor from B, showing increased expression in 
the dog’s tumor as compared to the hippocampus, normally the area of the canine brain with the 







Figure 4.7  
 
PC-3 immunostaining grades for 37 canine and 343 human astrocytomas. 500 tumor cells were 
graded for immunostaining quantity intensity and quantity. A PC-3 tumor grade was calculated 
using a mathematical formula, with cutoff values determined by natural breaks in the grading 
scheme. Note the conserved pattern of more intense PC-3 immunostaining for low histologic 
grade versus high histologic grade tumors, implying a similar molecular target in both dogs and 
humans. 92% of high histologic grade canine and 81% of high histologic grade human tumors 




PC-3 immunostaining grades for 26 canine and 104 human meningiomas. 500 tumor cells were 
graded for immunostaining quantity intensity and quantity. A PC-3 tumor grade was calculated 
using a mathematical formula, with cutoff values determined by natural breaks in the grading 
scheme.  92% of canine and 70% of human meningiomas overexpress PC-3 relative to normal 






Figure 4.9  
PC-3 immunostaining grades for 111 canine and 30 human oligodendrogliomas. 500 tumor cells 
were graded for immunostaining quantity intensity and quantity. A PC-3 tumor grade was 
calculated using a mathematical formula, with cutoff values determined by natural breaks in the 









Immunoblotting demonstrating PC-3 expression in all glioma cell lines evaluated. The three cell 






























Figure 4.11: Dose-response curves showing ten day, 4h pulse, PAC-1-mediated cytotoxicity in 








The GL261 (murine) glioma cell line is sensitive to 8h pulse PAC-1 therapy alone, radiation 
therapy alone, and combination PAC-1 with radiation therapy. The yellow star denotes 
calculated synergism between PAC-1 and radiation therapy via CI calculation, Bliss, and Loewe 
analysis. The skull and crossbones icon indicates nearly 100% cell death at biologically 
achievable doses of both therapies. Calculated combination index (CI): 0.145 at 0.79 uM PAC-1 















The U118-MG (human) glioma cell line is sensitive to 8h pulse PAC-1 therapy alone, radiation 
therapy alone, and combination PAC-1 with radiation therapy. The yellow star denotes 
calculated synergism via Bliss and Loewe analysis.  The skull and crossbones icon indicates 
nearly 100% cell death at biologically achievable doses of both therapies. Calculated 















The J3T-Bg (canine) glioma cell line is sensitive to 8h pulse PAC-1 therapy alone, radiation 
therapy alone, and combination PAC-1 with radiation therapy. The yellow star denotes 
calculated synergism via CI calculation, Bliss, and Loewe analysis. J3T-Bg is more resistant to 
both monotherapies and combination therapy. Calculated combination index (CI): 0.633 at 1 uM 












Figure 4.15  
 
Graphical representations of alternatively calculated drug synergism with Combenefit software, 









Table 4.1  
Calculated IC50 values for glioma and meningioma cell lines. For the pulse experiments, PAC-1 
was added to cell media for the number of hours indicated, followed by a change of fresh media 
during the 10-day treatment period. Radiation therapy was also performed once daily on a 10-
day treatment schedule. Some cell lines were also exposed to PAC-1 continuously for 8 days, 
and the IC50 values for these cell lines appear in the right-hand column.  
 
Cell Line Species 8h Pulse PAC-1 
IC50 
RTH IC50 8d IC50 
GL261 Mouse 0.1 µM 0.53 Gy 1.5 µM 
9L Rat 23.4 µM   
GO6A Canine 0.16 µM  1.2 µM 
J3T-Bg Canine 39 µM 1.4 Gy 3.9 µM 
SDT-3g Canine 14.7 µM 1.0 Gy 1.1 µM 
U118-MG Human 61 µM 0.93 Gy  
IOMM-Lee Human 36.3 µM   






Top, from left to right: A schematic coronal representation of the area of the brain in which 
tumor cells were injected; an MRI image of a mouse 10 days following tumor cell injection, 
verifying the appropriate location of cells; coronal brain section histology with tumor, 10 days 
following tumor cell injection.  
 
Middle and bottom: 200x and 400x views of the histopathological section of the tumor pictured 
in the top panel. There is marked cellular pleomorphism in the tumor cell population, with 
numerous mitotic figures, multinucleated cells, moderate to marked anisokaryosis and 
anisocytosis, and frequent karyomegaly.  
 
Schematic source:  
Paxinos G, Franklin KBJ. Mouse Brain in Stereotaxic Coordinates. 2nd ed. Boston, MA: 








A Kaplan-Meier plot showing survival curves for eight C57/BL6 mice with allografted gliomas. 
Blue line: vehicle control. Red line: 10 doses of 100 mg/kg PAC-1 were delivered orally, 








MRI and histopathological images from four mice, day 10 (left) and day 29 (middle and right) 
post-injection of 50,000 neurosphere-cultured GL261 syngeneic glioma cells into the right 
cerebral hemisphere. Note that tumor growth has occurred in each case.  
 
  
Control mouse with 122x tumor growth in 19 days 
PAC-1 mouse with 28x tumor growth in 19 days  
Combination therapy mouse with 116x tumor growth in 19 days 






MRI image of one mouse who received both PAC-1 and radiation therapy during the study 
period. Note that despite having evidence of macroscopic tumor burden on day 10 post-injection 
(left image), there was no evidence of a tumor at follow-up on day 29. On histopathologic 









Box plots showing outcome data for 18 tumor-bearing C57/BL6 mice with orthotopically 
implanted GL261 tumors. Mice in each treatment arm appeared to experience a beneficial 
treatment effect. Combination therapy appeared to be most effective in these mice; however, 
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